Organization Profile

You just read:

BioMarin Submits VIMIZIM™ (elosulfase alfa) NDS to Health Canada for the Treatment of Morquio A Syndrome Under Priority Review Status

News provided by

BioMarin

Dec 04, 2013, 08:00 ET